Press Releases
Celleron Therapeutics Begins a Pioneering Combination Therapy Approach to Treating Colorectal Cancer
Oxford, UK, 20th August 2018 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced the
Read MoreThe expansion cohort of our Phase I clinical trial is open to patient enrolment.
Read MoreThe company has selected Syneos Health, a leading biopharmaceutical solutions organization, to conduct clinical trials for its lead compound CXD101 in colorectal cancer.
Read MoreUK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.
Read MoreOxford 7 February 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced
Read MoreOxford, UK, 6 December 2017 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced
Read MoreOxford 13 November 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced
Read MoreOxford 24th July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced
Read MoreOxford 2 July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced
Read MoreOxford 24th May 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced
Read More